Bimergen Energy Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bimergen Energy Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $168.9K | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | $172.0K | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $209.4K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.84M | Mar 30, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $308 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $26.2K | Apr 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $308 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $26.2K | Apr 1, 2024 |
| FY2020 | Dec 31, 2020 | $172.0K | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | $94.1K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.18M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.28M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.43M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $1.34M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $1.07M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $1.98M | Mar 31, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.97M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($920.4K) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | ($811.6K) | Apr 1, 2024 |
| FY2023 | Dec 31, 2021 | ($285.0K) | Apr 1, 2024 |
| FY2021 | Dec 31, 2020 | ($297.4K) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($1.61M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($671.7K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($405.9K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($755.9K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.93M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.76M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($927.7K) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | ($861.9K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($285.0K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($335.4K) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($1.55M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($613.7K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($356.6K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($705.0K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $15.7K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $45.7K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $261.8K | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $50.2K | Mar 29, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $878.4K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($349.8K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($457.8K) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | ($789.3K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($162.7K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $447.0K | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $635.9K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($123.2K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($149.8K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $202.6K | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $3.6K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $50.1K | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $51.1K | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $9.4K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $5.0K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Apr 1, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.20M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $23.25M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $163.4K | May 30, 2025 |
| FY2023 | Dec 31, 2022 | $210.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.01M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $284.9K | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.16M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $3.40M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.99M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.37M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $1.66M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $1.82M | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $1.53M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $1.74M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $2.24M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $2.57M | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $1.56M | Mar 30, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $21.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $128.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $199.3K | May 30, 2025 |
| FY2023 | Dec 31, 2021 | $1.00M | Apr 1, 2024 |
| FY2023 | Jan 20, 2021 | $1.29M | Apr 1, 2024 |
| FY2021 | Dec 31, 2020 | ($248.4K) | Mar 16, 2022 |
| FY2021 | Dec 31, 2019 | $49.0K | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $1.66M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.33M | Mar 30, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $170.2K | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $170.2K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $170.2K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $170.2K | Mar 28, 2017 |
| FY2015 | Dec 31, 2014 | $170.2K | Mar 29, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.75M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($4.77M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.02M) | May 30, 2025 |
| FY2023 | Dec 31, 2022 | ($1.10M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($285.0K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($20.14M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($19.84M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($18.23M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($17.56M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($17.15M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $401.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $156.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $152.4K | May 30, 2025 |
| FY2023 | Dec 31, 2022 | $197.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $976.9K | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $41.7K | Mar 26, 2021 |
| FY2020 | Dec 31, 2019 | $110.6K | Mar 26, 2021 |
| FY2020 | Dec 31, 2018 | $59.7K | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $77.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $256.3K | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | May 30, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2015 | Dec 31, 2015 | 19.63M | Mar 29, 2016 |
| FY2015 | Dec 31, 2014 | 18.51M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Apr 1, 2013 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | May 30, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2015 | Dec 31, 2015 | 19.63M | Mar 29, 2016 |
| FY2015 | Dec 31, 2014 | 18.51M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Mar 30, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.93M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 5.12M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 3.46M | May 30, 2025 |
| FY2023 | Dec 31, 2022 | 515.51M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 20.24M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 20.24M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | 20.24M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 20.24M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 20.22M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 20.14M | Mar 29, 2018 |